Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.

Clics: 412
ID: 101498
2020
Métriques de Qualité et de Performance de l'Article
Qualité Globale
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Évaluation de la Qualité par IA
Non analysé
Readership in this journal
Emerging

Ranked #6 of 273 articles by views in the journal of clinical psychiatry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Résumé
Patients with schizophrenia and comorbid alcohol use disorder remain understudied. This post hoc analysis evaluated data from Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia study (January 2001-December 2004).Patients without substance abuse (except marijuana use) in the month before study entry were categorized into those with a history of alcohol use disorder (SZ + AUD) within 5 years before study entry and those without alcohol use disorder (SZ-only) per DSM-IV criteria. Time to first and recurrent exacerbations and hospitalizations were compared between disease states and between olanzapine and perphenazine, quetiapine, risperidone, and ziprasidone.A total of 1,338 patients (SZ + AUD = 22.6%; SZ-only = 77.4%) were included. Time to first exacerbation of SZ was significantly shorter in the SZ + AUD versus SZ-only population (median = 5.4 vs 6.4 months; hazard ratio [HR] = 1.20 [95% CI, 1.01-1.42]; P = .039). Similar findings were observed for first hospitalization (HR = 1.63 [95% CI, 1.20-2.22]; P = .002) and recurrent hospitalizations (HR = 1.60 [95% CI, 1.18-2.15]; P = .002). The most common reasons leading to exacerbation in both groups were an increase in symptom severity and lack of efficacy. In patients with SZ + AUD related or unrelated to marijuana, perphenazine, quetiapine, risperidone, and ziprasidone were associated with significantly shorter time to first exacerbation versus olanzapine.This post hoc analysis confirmed that patients with SZ + AUD had a worse illness course than patients with SZ-only and suggests that olanzapine may be associated with a longer time to first and recurrent exacerbations versus other antipsychotics in this difficult-to-treat population. Further research is needed to identify effective treatments for this important yet understudied patient population.ClinicalTrials.gov identifier: NCT00014001.
Clé de Référence
pathak2020coursethe Utilisez cette clé pour citer automatiquement dans le manuscrit lors de l'utilisation de SciMatic Manuscript Manager ou Thesis Manager
Auteurs Sanjeev Pathak, Ying Jiang, Lauren DiPetrillo, Mark S Todtenkopf, Yan Liu, Christoph U Correll
Are you one of these authors? Claim your profile
Revue the journal of clinical psychiatry
Année 2020
DOI
10.4088/JCP.19m12731
URL
Mots-clés
Epidemiology treatment coronavirus disease 2019 epidemic prevention and control

Citations

Aucune citation trouvée. Pour ajouter une citation, contactez l'administrateur à info@scimatic.org

Commentaires

Aucun commentaire pour le moment. Soyez le premier à commenter cet article.